Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus’ require investigation to understand pathogen biology and pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is widespread, and treatments to control potentially deleterious host responses are lacking.
The ISARIC study aims to develop a mechanistic understanding of disease processes, so that risk factors for severe illness can be identified and treatments can be developed.
When patients are confirmed to have corona virus, the research team will ask them to participate into this study. The participant will be consenting to provide blood, urine and faecal samples throughout their admission at day 1, 3 and 9, with a final follow up completed at day 28.
Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.